Vesalio has announced it has expanded the distribution of the NeVa Thrombectomy System, gaining market coverage in 53 countries in Europe, Latin America, Asia and the Middle East.
Vice president of the company for international business, William von Brendel, says that “the expansion of the NeVa product line and impressive clinical data are driving strong interest from top distribution companies globally, accelerating our growth momentum. We expect to add additional markets by the end of 2020 and into 2021 as we approach US FDA (Food and Drug Administration) clearance.”
To support the onboarding of stroke centres in the expanded markets, Vesalio has broadened its training programs to include Neva Induction Webinars, which has allowed Vesalio to onboard over 20 stroke centres in the past three months.
Diane Demet Tangun, vice president of market development claims that “enhancing virtual training was necessary given the limitations posed by the pandemic and the desire of new physicians to utilise Vesalio’s Drop Zone technology.”
A recent NeVa publication by Akpinar et al. in Interventional Neuroradiology has reported significant first-pass recanalisation rates in a multi-centre, real-life setting.
“The data from this study is particularly compelling as the high rate of first pass success was achieved largely without the use of balloon guide catheters, which demonstrates the effectiveness and versatility of the NeVa platform”, says Tangun.